[Skip to Navigation]
Comment & Response
November 2017

Risk of Intraocular Bleeding and the New Anticoagulants: Not Such a Big Effect—Reply

Author Affiliations
  • 1South Australian Institute of Ophthalmology, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia
  • 2Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
  • 3Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom
JAMA Ophthalmol. 2017;135(11):1281-1282. doi:10.1001/jamaophthalmol.2017.4024

In Reply We appreciate the commentary by Wormald and Evans on our article.1 In this systematic review and meta-analysis of randomized clinical trials that enrolled patients with atrial fibrillation and venous thromboembolism, a 22% relative reduction in intraocular bleeding with novel anticoagulants compared with warfarin resulted in an absolute risk reduction of 0.8 bleeds per 1000 person-years.

Add or change institution